Trial Profile
An Open-label, Randomized, Single Intravenous Dosing Study to Investigate the Effect of Fixed-dose Combinations of Tenofovir/Lamivudine or Atazanavir/Ritonavir on the Pharmacokinetics of Remdesivir in Ugandan Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2021
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary) ; Atazanavir/ritonavir; Lamivudine/tenofovir
- Indications Acquired immunodeficiency syndrome; Ebola virus infections; HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms RemTLAR
- 19 Aug 2021 Status changed from not yet recruiting to completed.
- 15 May 2020 New trial record